Does Orforglipron Affect Birth Control? What the Foundayo Label Says

Yes — orforglipron (Foundayo) can potentially affect how oral birth control pills are absorbed, according to its FDA-approved label. The label advises that anyone using an oral hormonal contraceptive switch to a non-oral method, or add a barrier method, for 30 days after starting orforglipron and for 30 days after each dose increase. Here’s exactly what the label says and why it matters.

What does the FOUNDAYO label say about birth control?

Per the FDA-approved FOUNDAYO label on DailyMed, the effect of orforglipron on oral contraceptive absorption hasn’t been directly evaluated in a clinical trial. But because orforglipron — like other GLP-1 receptor agonists — can delay gastric emptying, and delayed gastric emptying may affect how other oral medications are absorbed, the label takes a precautionary approach: patients using oral hormonal contraceptives are advised to switch to a non-oral contraceptive method, or add a barrier method, for 30 days after initiating orforglipron and for 30 days after each dose escalation.

That last part matters. Orforglipron isn’t started at a full dose — it’s titrated upward in steps over several months, typically from 0.8 mg up through higher maintenance doses. Each of those step-ups can, per the label’s guidance, warrant another 30-day window of backup contraception, not just the very first month of treatment.

Why would a pill for weight loss affect birth control at all?

The connection isn’t about hormones interacting directly — it’s about the stomach. GLP-1 receptor agonists, orforglipron included, work partly by slowing gastric emptying: food (and other things you swallow) move through the stomach and into the small intestine more slowly than usual. That’s part of how these medications reduce appetite.

The tradeoff is that anything else taken orally around the same time — including a birth control pill — can, in principle, be absorbed differently when gastric emptying is slower. That’s the mechanism behind the label’s caution, even though no dedicated interaction study has been published confirming exactly how much absorption changes.

Which birth control methods does this actually affect?

Contraceptive type	Affected by this precaution?
Oral hormonal contraceptives (the pill)	Yes — label advises non-oral method or added barrier method for 30 days after start and each dose increase
Non-oral hormonal methods (implants, injections, patches, IUDs)	No — not oral, not subject to this labeled precaution
Barrier methods (condoms, etc.)	Not affected — and this is exactly what the label says to add during the precaution windows

The label’s guidance is specific to oral hormonal contraceptives, because the concern is gastrointestinal absorption. Methods that don’t pass through the digestive system — implants, injections, patches, and IUDs — aren’t implicated by this same mechanism.

How does this play out across a titration schedule?

Because orforglipron is dosed in steps, the practical picture looks something like this: a 30-day precaution window when you first start the pill, then another 30-day window each time your prescriber moves you up a dose level. If you’re on oral contraception and going through a multi-month titration schedule (our step-by-step guide to taking orforglipron and Foundayo dosing overview cover the full timeline), that can mean more than one backup-contraception window over the course of getting to a maintenance dose — not a single 30-day period at the very start.

If you’re switching to orforglipron from another GLP-1 rather than starting fresh, the same logic applies at whatever dose-escalation points are part of your specific plan — see our guide on switching to orforglipron for what that transition generally involves.

What does the label’s guidance look like as a timeline?

Since the label’s guidance is date-driven, it helps to see it laid out as a sequence rather than prose:

1. Before starting orforglipron: the label supports discussing your oral hormonal contraceptive use with your prescriber so the 30-day windows can be planned around your dosing schedule.
2. The first 30 days after your first dose: per the label, switch to a non-oral contraceptive method, or add a barrier method (like condoms), alongside your oral contraceptive.
3. Each dose escalation: the label’s 30-day precaution applies again every time your prescriber steps up your orforglipron dose — not just at the start.
4. Between escalation windows: once a 30-day window passes, the label’s guidance doesn’t call for ongoing backup protection until the next dose increase.
5. If your escalation schedule is unclear: your prescriber sets the specific plan and can tell you when the next dose change — and next 30-day window — is expected.

If a window is missed, the label doesn’t characterize it as an emergency, but it does mean the absorption concern the label describes applies without backup protection in place during that time — worth raising with your prescriber or OB-GYN.

This is educational information, not medical advice

This article summarizes what the FDA-approved FOUNDAYO label states about oral contraceptive absorption — it isn’t personalized medical advice, and it isn’t a substitute for a conversation with your prescriber or OB-GYN. Whether you need backup contraception, which method makes sense for you, and how to time it around your specific dose schedule are questions for the clinician managing both your GLP-1 treatment and your contraception. Oral GLP-1s can carry their own administration cautions for other reasons, too — Rybelsus (oral semaglutide), for instance, has strict empty-stomach and water-timing rules tied to its absorption method, per MedlinePlus, even though that particular rule isn’t the same gastric-emptying concern discussed here. If you’re also managing side effects during titration, our orforglipron side effects guide covers what’s common and how it’s typically managed.

Bottom line

Orforglipron’s FDA label advises that anyone on oral hormonal birth control switch to a non-oral method, or add a barrier method, for 30 days after starting the medication and for 30 days after every subsequent dose increase — a precaution based on orforglipron’s known effect on gastric emptying, even without a dedicated interaction trial. Non-oral contraceptive methods aren’t implicated by this same concern. If you’re starting or titrating orforglipron and currently use an oral contraceptive, talk to your prescriber or OB-GYN about backup protection before your next dose change.